Alivus Life Sciences: Should You Buy, Hold, or Sell Right Now?

Alivus Life Sciences share price is trading close to its 52-week high of Rs 1,493.80, with Alivus Life Sciences share price around Rs 1,379 on the NSE, more than 68 percent above its 52-week low of Rs 819. With a record profit quarter driven by strong margin expansion, investors are asking whether this API and CDMO maker is a stock to buy near its highs, a hold, or a sell.

This Alivus Life Sciences stock analysis walks through the Q1 FY27 numbers, the shift toward the higher-margin non-GPL business, valuation against the pharma sector, shareholding pattern and the technical setup, using figures sourced from company disclosures and investor communications.

Click Here – Get Free Investment Predictions

About Alivus Life Sciences

Keep this backdrop in mind when reading the rest of this Alivus Life Sciences share price review. Before deciding on Alivus Life Sciences share price, it helps to understand the underlying business. Alivus Life Sciences Ltd., formerly known as Glenmark Life Sciences, manufactures active pharmaceutical ingredients (APIs) and provides contract development and manufacturing organisation (CDMO) services, with a business increasingly weighted toward non-GPL customers beyond its original Glenmark Pharmaceuticals relationship.

The company is part of the Nirma group following the change in majority ownership, and its non-GPL business, comprising sales to customers other than Glenmark Pharmaceuticals, has grown to represent 89 percent of total revenue, up from 75 percent a year earlier, reflecting successful diversification of its customer base.

Alivus Life Sciences Share Price Today: Key Levels

The table below summarises where Alivus Life Sciences share price stands right now against its recent trading range and market value.

Metric	Value
Alivus Life Sciences CMP (NSE)	Rs 1,379.10
Alivus Life Sciences CMP (BSE)	Rs 1,381.50
52-Week High	Rs 1,493.80
52-Week Low	Rs 819.00
Market Capitalisation	Approximately Rs 17,416 crore

Alivus Life Sciences share price is trading close to its 52-week high, more than 68 percent above its 52-week low, reflecting very strong investor confidence in the company's margin expansion and customer diversification.

Check the Univest Screener for Live Stock Data

Alivus Life Sciences Financial Performance

Track this line item closely if you are following Alivus Life Sciences share price closely. The Alivus Life Sciences share price trend is closely tied to how these numbers evolve each quarter. Alivus Life Sciences reported Q1 FY27 (June 2026 quarter) revenue from operations of Rs 640.41 crore, up 6.4 percent year on year from Rs 601.85 crore, though down 7.1 percent sequentially due to the GPL business's historical skew toward the second half of the fiscal year. Net profit rose 31.7 percent year on year to a record Rs 160.08 crore, the company's highest-ever quarterly PAT, with PAT margin expanding to 25 percent from 20.19 percent a year earlier.

EBITDA for the quarter reached Rs 234 crore, up 29.1 percent year on year, with EBITDA margin expanding 650 basis points to 36.6 percent. The non-GPL business grew 26.5 percent year on year and now contributes 89 percent of revenue, up from 75 percent a year earlier, while the legacy GPL segment declined 52.6 percent due to inventory rationalization, with management expecting recovery in the second half of FY27. The company maintained its full-year guidance of 10 to 12 percent revenue growth and 30 to 32 percent EBITDA margins, and remains net debt-free with cash reserves of Rs 8,802 million.

Period	Revenue	Net Profit	Comment
Q1 FY27 (Jun 2026)	Rs 640.41 crore	Rs 160.08 crore	+6.4% revenue, +31.7% profit YoY; record quarterly PAT

Valuation Check: Is Alivus Life Sciences Share Price Expensive?

It is one of the clearest signals available on Alivus Life Sciences share price today. Any view on Alivus Life Sciences share price should start from these valuation multiples. Alivus Life Sciences share price currently reflects a price to earnings ratio of about 28.88 times trailing earnings, a discount to the broader pharmaceutical sector average of roughly 51.2 times. The price to book ratio stands near 5.2 times, supported by a strong 16.94 percent return on equity.

Debt to equity of 0.02 is very low, and the company is net debt-free with a strong cash position. Given the record quarterly profit and successful shift toward the higher-margin, more diversified non-GPL business, this discount to the pharma sector could offer room for re-rating if the margin expansion trend continues as guided.

Technical Signals: What the Chart Shows

Price action here often foreshadows the next move in Alivus Life Sciences share price. Alivus Life Sciences share price is currently positioned roughly 8 percent below its 52-week high of Rs 1,493.80 and more than 68 percent above its 52-week low of Rs 819, reflecting a very strong overall run over the past year. A stock trading this close to its high, backed by a record profit quarter, typically signals the market rewarding tangible execution in the company's business diversification strategy.

Trading volumes remain heavy, so investors should track Alivus Life Sciences share price alongside the expected recovery in the GPL segment during the second half of FY27 and continued non-GPL growth, rather than reacting to any single day's move at these technical levels.

Download the Univest iOS App or Univest Android App to track Alivus Life Sciences' live price and technical levels.

Shareholding Pattern

Shifts here can influence Alivus Life Sciences share price more than headline news on some sessions. Alivus Life Sciences, formerly Glenmark Life Sciences, is part of the Nirma group following the change in majority ownership. A detailed current promoter, FII and DII percentage breakdown was not consistently available across sources at the time of writing and should be verified on the company's latest exchange filing.

Why Investors Are Watching Alivus Life Sciences

• Record quarterly profit with strong margin expansion: Q1 FY27 delivered the company's highest-ever quarterly PAT, with EBITDA margin expanding 650 basis points to 36.6 percent.
• Successful customer diversification: The non-GPL business now contributes 89 percent of revenue, up from 75 percent a year earlier, reducing dependence on the legacy GPL relationship.
• Net debt-free with strong cash reserves: A very low debt to equity ratio of 0.02 alongside cash reserves of Rs 8,802 million gives the company significant financial flexibility.
• Discount valuation to sector: A 28.88x PE against a 51.2x pharmaceutical sector average offers meaningful valuation cushion given the strong recent execution.

Risks and Factors to Watch

• GPL segment decline: The legacy GPL business declined 52.6 percent year on year due to inventory rationalization, and its expected recovery in the second half of FY27 needs to materialise as guided.
• Sequential revenue decline: Q1 FY27 revenue fell 7.1 percent sequentially, reflecting the GPL business's historical skew toward the second half of the fiscal year, a seasonal pattern investors should factor in.
• API and CDMO sector competitive pressure: Alivus Life Sciences competes against other domestic and global API manufacturers and CDMO service providers.
• Margin normalisation risk: Management's own guidance of 30 to 32 percent EBITDA margins for the full year suggests some normalisation from the exceptional 36.6 percent achieved in Q1 FY27.

Alivus Life Sciences Share Price Target: What the Data Suggests

Until then, Alivus Life Sciences share price remains best tracked through live, verified data rather than a single fixed number. Alivus Life Sciences does not have a single widely published, current analyst consensus 12-month share price target consistently available at this time. What the data shows is a company delivering record profitability with successful customer diversification, trading at a discount to the pharmaceutical sector.

Investors who want live, updated research can check the Univest Screener, and should consult a SEBI-registered investment adviser for guidance tailored to their own goals.

Alivus Life Sciences: Should You Buy, Hold, or Sell Right Now?

This is the core question behind Alivus Life Sciences share price right now. The Alivus Life Sciences buy or sell decision depends on whether you believe the GPL segment recovery and continued non-GPL growth will sustain the current momentum.

The case for buying: Investors who believe in the company's successful diversification away from its legacy GPL relationship, and who value the net debt-free balance sheet and record profitability, may find the discount to sector PE attractive despite the stock's proximity to its 52-week high.

The case for holding: Existing shareholders who already track Alivus Life Sciences' margin story may prefer to stay invested and monitor continued execution.

The case for waiting: Investors wanting to see the expected GPL segment recovery materialise in the second half of FY27 before committing fresh capital may prefer to wait for that confirmation.

Historically, API and CDMO companies successfully diversifying their customer base have rewarded patient investors, so weigh this against your own risk tolerance and consult a SEBI-registered investment adviser if unsure.

Conclusion

Alivus Life Sciences share price reflects an API and CDMO manufacturer delivering a record Q1 FY27 profit with strong margin expansion, driven by successful diversification of its customer base beyond its legacy GPL relationship, trading close to its 52-week high at a discount to the pharmaceutical sector. This article is for informational purposes and not a personalised investment recommendation.

Q1. Is Alivus Life Sciences a good stock to buy right now?

Ans. Alivus Life Sciences delivered a record Q1 FY27 quarterly PAT of Rs 160.08 crore, up 31.7 percent year on year, driven by strong margin expansion and successful diversification toward its non-GPL business. The stock trades at a discount to the pharma sector, which may appeal to investors who believe in this diversification story.

Q2. What is the Alivus Life Sciences share price today?

Ans. Alivus Life Sciences share price is trading around Rs 1,379 on the NSE, close to its 52-week high of Rs 1,493.80. The stock's 52-week low is Rs 819.

Q3. What is the Alivus Life Sciences share price target?

Ans. Alivus Life Sciences does not have a single widely published, current analyst consensus 12-month share price target consistently available at this time. Investors can check live research on the Univest Screener and consult a SEBI-registered adviser.

Q4. Was Alivus Life Sciences formerly known as Glenmark Life Sciences?

Ans. Yes, Alivus Life Sciences Ltd. was formerly known as Glenmark Life Sciences before rebranding, and is now part of the Nirma group following a change in majority ownership.

Q5. What is Alivus Life Sciences' market capitalisation and PE ratio?

Ans. Alivus Life Sciences has a market capitalisation of approximately Rs 17,416 crore and trades at a price to earnings ratio of about 28.88 times, a discount to the pharmaceutical sector average PE of roughly 51.2 times.

Q6. Why did Alivus Life Sciences' GPL business decline?

Ans. Alivus Life Sciences' legacy GPL business, sales to Glenmark Pharmaceuticals, declined 52.6 percent year on year in Q1 FY27 due to inventory rationalization, with management expecting a recovery in the second half of FY27.